GID.AX - GI Dynamics, Inc.

ASX - ASX Delayed Price. Currency in AUD
0.0190
-0.0010 (-5.00%)
At close: 10:39AM AEDT
Stock chart is not supported by your current browser
Previous close0.0200
Open0.0190
Bid0.019 x 0
Ask0.020 x 0
Day's range0.0190 - 0.0190
52-week range0.0160 - 0.0430
Volume123,158
Avg. volume54,219
Market cap18.314M
Beta (3Y monthly)3.40
PE ratio (TTM)N/A
EPS (TTM)-0.014
Earnings date13 Aug 2018 - 17 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.03
  • Business Wire15 days ago

    GI Dynamics Appoints Vice President of Clinical and Regulatory Affairs

    GI Dynamics® Inc. (GID.AX), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the appointment of Stephen Linhares to the position of vice president of clinical and regulatory affairs. Linhares’ role with GI Dynamics will focus on the pivotal trial of EndoBarrier in the United States (GID 18-1) and the clinical trial of EndoBarrier in India with Apollo Sugar.

  • Business Wire2 months ago

    GI Dynamics Announces Agreement with Apollo Sugar to Study EndoBarrier in India

    Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity. GI Dynamics Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce that it has entered today into an agreement with Apollo Sugar1 to jointly study the safety and efficacy of EndoBarrier in India. Apollo Sugar is a collaboration between Apollo Health & Lifestyle Limited and Sanofi2.

  • Business Wire2 months ago

    GI Dynamics Announces Close of Second Tranche of Placement and Grant of Options to CEO

    GI Dynamics®, Inc. (GID.AX), a medical device company that is developing EndoBarrier® is pleased to announce that, following stockholder approval obtained on 30 October 2018 at the Company’s Special Meeting, it has successfully completed the issue of the CHESS Depositary Interests (CDIs), the subject of the second tranche of the Placement that was detailed further in the Company’s 20 September 2018 announcement. Under the second tranche of the Placement, GI Dynamics has today issued 197,222,250 CDIs (representing 3,944,445 shares of common stock) to certain sophisticated and professional investors in the United States, Australia and Guernsey at an issue price of AUD$0.02 per CDI raising a total of AUD$3,944,445 (USD$2,840,000).

  • GI Dynamics Announces Results of Special Meeting
    Business Wire2 months ago

    GI Dynamics Announces Results of Special Meeting

    GI Dynamics, Inc. (GID.AX), a medical device company that is developing EndoBarrier, held a Special Meeting on Monday, 29 October 2018 at 5:00pm United States Eastern Daylight Time (being Tuesday, 30 October 2018 at 8:00am Australian Eastern Daylight Time) and is pleased to announce that each of the resolutions put to stockholders as set forth in the Proxy Statement dated 15 October 2018 (Proxy Statement), were passed. As specified in the Proxy Statement, the Company notes that the CDIs to be issued to Crystal Amber Fund Limited (or its nominee) and certain sophisticated and professional investors in Australia and the United States under the second tranche of the Placement will be issued after receipt of all second tranche funds and will rank equally in all respects with CDIs on issue at the date of allotment.

  • Business Wire3 months ago

    GI Dynamics Announces Selection of New Notified Body

    GI Dynamics, Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to announce the selection of Intertek as the company’s notified body to continue working toward attaining the EndoBarrier CE Mark. GI Dynamics selected Intertek for its medical device expertise and availability to support the clinical and regulatory requirements of EndoBarrier and GI Dynamics.

  • Business Wire4 months ago

    GI Dynamics Announces AUD $6.9m Private Placement to be Completed in Two Tranches

    GI Dynamics, Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary Interests (CDIs) of the Company (representing 6,944,445 shares of common stock) at an issue price of AUD $0.020 per CDI to certain sophisticated and professional investors in Australia, the United States, and the United Kingdom to raise approximately AUD $6.944 million (representing approximately USD $5 million using an exchange rate of USD $0.72 per AUD) (Placement). The issue of CDIs under the Placement will occur in two tranches.

  • Business Wire5 months ago

    GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial

    GI Dynamics Inc. (GID.AX), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received approval of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in a pivotal trial evaluating the safety and efficacy of EndoBarrier in the United States pending Institutional Review Board (IRB) approval.

  • Who Are The Largest Shareholders In GI Dynamics Inc (ASX:GID)?
    Simply Wall St.7 months ago

    Who Are The Largest Shareholders In GI Dynamics Inc (ASX:GID)?

    In this analysis, my focus will be on developing a perspective on GI Dynamics Inc’s (ASX:GID) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...

  • Business Wire8 months ago

    EndoBarrier Meta-Analysis Published in Diabetes Care Journal

    GI Dynamics® Inc. , a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes,” by Pichamol Jirapinyo, MD, of Brigham and Women’s ...

  • Business Wirelast year

    GI Dynamics Announces AUD $2.05m Private Placement and Close of First Tranche of AUD ~$1m

    GI Dynamics®, Inc. , a medical device company that is developing EndoBarrier® is pleased to announce that it has received binding commitments for a private placement of 58,780,619 CHESS Depositary Interests of the Company at an issue price of AUD $0.035 per CDI to sophisticated and professional investors in Australia, the United States, and the United Kingdom to raise approximately AUD $2.05 million ...